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BENEFICIOS EN LA MICROBIOTA INTESTINAL
DESPUÉS DE LA SUPLEMENTACIÓN CON 
INULINA Y LA GOMA GUAR PARCIALMENTE
HIDROLIZADA – UN ENSAYO CLÍNICO 
ALEATORIZADO EN MUJERES 
CON ESTREÑIMIENTO
Resumen
Introducción: Los prebióticos influyen positivamente
en la composición de la microbiota intestinal, mejorando
así la función intestinal. Estas propiedades pueden ser
útiles para el tratamiento del estreñimiento. 
Objetivos: Este estudio evaluó la tolerancia y la eficacia
de una mezcla de prebiótico inulina con la goma guar par-
cialmente hidrolizada (I-PHGG) para el tratamiento de
mujeres con estreñimiento, así como su influencia en la
composición de la microbiota intestinal y la producción
de ácidos grasos de cadena corta.
Métodos: Nuestro estudio contó con la participación de
60 mujeres voluntarias con estreñimiento y profesionales
de la salud. Las participantes informaron tener menos de
tres evacuaciones por semana y fueron asignadas aleato-
riamente a tratamiento con prebióticos o placebo. El trata-
miento consistió en 3 semanas de suplementación con 15 g
d I-PHGG (grupo de fibras) o maltodextrina (grupo pla-
cebo). Malestar abdominal, flatulencia, consistencia de las
heces, y los movimientos intestinales se evaluaron mediante
un cuestionario de registro diario y una entrevista semanal.
Cambios en la población de bacterias fecales y los ácidos
grasos de cadena corta fueron evaluados por PCR en
tiempo real y cromatografía de gases, respectivamente. 
Resultados: Hubo un aumento en la frecuencia de las
evacuaciones intestinales por semana y la satisfacción del
paciente, tanto en la fibra y el grupo placebo, sin diferen-
cias significativas. El total de Clostridium sp disminuyó
significativamente en el grupo de fibras (p = 0,046) y
aumentó en el grupo placebo (p = 0,047). No hubo cam-
bios en el perfil fecal de ácidos grasos de cadena corta.
Conclusiones: El consumo de I-PHGG ha producido
resultados clínicos comparables a placebo en mujeres con
estreñimiento, pero ofreció otros efectos protectores
sobre la microbiota intestinal al disminuir la cantidad de
bacterias patológicas de lo género Clostridium.
(Nutr Hosp. 2011;27:123-129)
DOI:10.3305/nh.2012.27.1.5445
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Abstract
Introduction: Prebiotics positively affect gut micro-
biota composition, thus improving gut function. These
properties may be useful for the treatment of constipa-
tion.
Objectives: This study assessed the tolerance and effec-
tiveness of a prebiotic inulin/partially hydrolyzed guar
gum mixture (I-PHGG) for the treatment of constipation
in females, as well as its influence on the composition of
intestinal microbiota and production of short chain fatty
acids.
Methods: Our study enrolled 60 constipated female
health worker volunteers. Participants reported less than
3 bowel movements per week. Volunteers were random-
ized to treatment with prebiotic or placebo. Treatment
consisted of 3 weeks supplementation with 15 g/d I-
PHGG (fiber group) or maltodextrin (placebo group).
Abdominal discomfort, flatulence, stool consistency, and
bowel movements were evaluated by a recorded daily
questionnaire and a weekly interview. Changes in fecal
bacterial population and short chain fatty acids were
assessed by real-time PCR and gas chromatography,
respectively.
Results: There was an increased frequency of weekly
bowel movements and patient satisfaction in both the
fiber and placebo groups with no significant differences.
Total Clostridium sp significantly decreased in the fiber
group (p = 0.046) and increased in the placebo group (p =
0.047). There were no changes in fecal short chain fatty
acid profile. 
Conclusions: Consumption of I-PHGG produced clini-
cal results comparable to placebo in constipated females,
but had additional protective effects on gut microbiota by
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Constipation is a very common condition in the gene -
ral population, both in adults and children.1 According to
a study in the United States, the prevalence of constipa-
tion in adults is 2-28% and is higher among females.2,3
Constipation uses significant healthcare resources and its
control is a target for reducing healthcare expenditures. 
Among the causes for constipation in adults is inade-
quate dietary fiber intake.4 Insoluble fibers, such as
bran, have been traditionally used to control adult con-
stipation with satisfactory results.5-7 However, soluble
and prebiotic fibers have several advantages and have
also been studied for constipation control.8,9
The concept of prebiotics as “a non-digestible food
ingredient that beneficially affects the host by selec-
tively stimulating the growth and/or activity of one or a
limited number of bacteria in the colon” arose from the
observation that inulin and fructooligosaccharides
selectively stimulate the growth of bifidobacteria,
which are considered beneficial for human health.8-12
If prebiotics modulate gut microbiota, they might
also influences gut function by reducing intestinal pH,
increasing stool weight and bowel movements, and
exerting an osmotic effect that increases water content
in the colon. These properties may be useful for the
treatment of constipation.13
Dietary fiber and non-digestible oligosaccharides are
the main growth substrates of gut microorganisms14 As
bacterial metabolism in the human colon is primarily
anaerobic, these substrates are fermented and can poten-
tially form short chain fatty acids (SCFA) that serve as
local fuels and may regulate cellular processes.12,15
Partially hydrolyzed guar gum (PHGG) is a water
soluble and non-gelling fiber associated with reduced
constipation in females and relief of abdominal pain in
patients with irritable bowel syndrome.16,17 Currently,
there is available a mixture of fibers that combines
PHGG with the prebiotic activity of inulin. The mix-
ture of these two fibers could maximize their individual
effects and provide benefits for health and bowel func-
tion, growth of beneficial bacteria, and increased fer-
mentation activity in the intestine. Together, these
properties may be beneficial for constipated patients.
This study evaluated the efficacy and tolerance of
the combination of oral inulin with PHGG as prebiotics
in female patients with constipation. We also analyzed
its influence on the composition of intestinal micro-
biota and production of SCFA.
Patients and methods
Ethical issues
The current study was carried out following the ethi-
cal recommendations of the Declaration of Helsinki
and the Ethical Committees “Comitê de Ética em
Pesquisa do Hospital das Clínicas de São Paulo” and
“Comitê de Ética do hospital São Joaquim and Hospital
São José da Real e Benemérita”, which approved the
study protocol. All subjects gave written informed con-
sent and were selected and followed by a research team
at Ganep at Hospital da Real e Benemérita Associação
Portuguesa de Beneficiência de São Paulo. 
Subjects
Adult (18-65 years) female volunteers (n = 60) with
at least 3 months of constipation defined as less than 3
bowel movements per week were recruited among
health workers from the Hospital da Real e Benemérita
Beneficência Portuguesa de São Paulo. None of the
recruits used laxatives or enemas. Criteria for exclu-
sion were constipation secondary to pharmacological
effects, use of drugs that influence intestine motility,
narcotic or alcohol use, being pregnant or lactating,
lactose intolerance, habitual consumption of lactic acid
bacteria-containing food or prebiotics, any historical or
current diagnosis of large bowel disease such as
inflammatory bowel disease and colon cancer, and his-
tory of neurologic disorder. 
Experimental Design 
This study was a randomized, double-blind, placebo
controlled trial. After four days of treatment adaptation
with increased consumption of fiber or placebo, treat-
ment consisted of three weeks supplementation with 15
g/d of a mixture of inulin and PHGG (fiber group) or 15
g/d of maltodextrin (placebo group) divided in three
sachets (5 g each). Subjects were required to record daily
the sachet consumption and advised to maintain their
daily physical activity, life style, and sleeping habits. 
Gastrointestinal response including abdominal dis-
tension and pain, flatulence, stool consistency (classi-
fied according to Lewis 1997), and bowel movement
were also recorded daily.18
Fresh stools were collected individually in plastic
bags and immediately sent to laboratory in an ice
bucket to be weighed and blended, fractionated, and
stored for further determination of the fecal microbiota
and SCFA content. All laboratory procedures were per-
formed by researchers at the Metanutri team from the
Department of Gastroenterology of the University of
São Paulo Medical School.
Efficacy of treatment
The efficacy and tolerance of treatment were based
on self-recording of gastrointestinal response and a
weekly interview. At the interview, physicians and
dieticians evaluated the frequency of bowel movement
and subject satisfaction in relation to bowel move-
ments.
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Quantification of fecal bacteria 
We studied the non-pathogenic bacteria of the gen-
era Bifidobacterium and Lactobacillus and the patho-
genic bacteria of the genera Bacteroides and Clostrid-
ium and the species Escherichia coli. Bacterial DNA
was extracted and purified from stool samples
(200mg) using the kit Qiamp DNA Stool Mini Kit
(Qiagen, USA). Its integrity was determined on 2%
agarose gel and its concentration in a spectropho-
tometer (Nanodrop, USA). DNA samples remained at
-20°C freezer for later quantitative analysis by real-
time polymerase chain reaction (real-time PCR).
Total DNA of bacteria strains cultured in blood agar
at 37°C and under anaerobic conditions (table I) was
extracted and purified using the gDNA mini
ChargeSwict bacteria (Invitrogen, USA) to be used as
positive control of real-time PCR. 
Changes in fecal bacterial population were
assessed using real-time PCR through the absolute
quantification of bacterial 16S ribosomal DNA
(rDNA) genes by using specific primers to the 16S
site of ribosomal DNA (Table 1). The number of
genes copies was determined using Platinum® SYBR
Green qPCR Supermix UDG (Invitrogen, USA) and
the reactions were developed according to the manu-
facturer’s protocol. In absolute quantification, the
number of interest genes copies was determined
based on the number of copies of curve pattern con-
structed by cloning into plasmid DNA. Cloning of
16S rDNA of different genera and species of studied
bacteria was performed following the protocol of the
kit TOPO TA Cloning Kit for Sequencing (Invitro-
gen®, USA). After cloning, the DNA plasmid contain-
ing the cloned 16S rDNA was extracted and purified.
Quantification of plasmid DNA was determined
using Nanodrop ND-1000 spectrophotometer. The
concentration found was used to determine the calcu-
lation of molecules/mL. The plasmid DNA was stored
at -20º C and was used to determine the standard
curve of real-time PCR by serial dilution of different
genes of interest. 
Fecal SCFA Content
The quantification of fecal SCFA (acetic, propionic,
isobutyric, butyric, isovaleric, and valeric acid) was
developed by gas chromatography. Fecal samples (1 g)
were diluted in water at 4°C and mixed for 5 minutes.
The suspension was adjusted to a pH of 2 to 3 with 5M
hydrochloric acid and the sample was centrifuged for 20
minutes at 5,000 rpm and 4°C. After centrifugation, the
supernatant was collected and analyzed using a gas chro-
matograph (GC-Shimatzu model 2010F, Japan)
equipped with auto injector (Shimadzu Model AOC-20i,
Japan), split/splitless injector (Shimadzu model SPL-
2010, Japan), flame ionization detector (FID-2010
model Shimadzu, Japan), and Cilicia capillary column
(30 m x 0.25 mm internal diameter and 0.25 mm in film;
Nukol, 30 m x 0.25 mm ID, 0.25 μm film- Supelco,
Japan). A pattern of SCFA (volatile acid standard mix-
Supelco, Japan) was used to enable the identification and
analysis of the peaks generated by gas chromatography.
The concentrations of various SCFA by analysis by gas
chromatography were corrected in relation to dry weight
of the samples. The initial temperature of the oven was
100°C and this was raised to 185°C at 4°C/min. The
temperature of the injection port and detector was 240°C
and 250°C, respectively. The flow rate of carrier gas
(H2) was adjusted to split injection. 
Statistical analysis
Quantitative data from bowel microbiota and SCFA
were evaluated on a log basis using the Student T test to
compare T0 (before treatment) and T1 (after treatment)
within and between treatment groups (fiber and
placebo). The variation between T0 and T1 was also
compared between groups using the Wilcoxon test.
The frequency of bowel movement and subject satis-
faction were evaluated by Fisher exact test for each
evaluated period (weekly) and by qui-quadrate for total
studied period (3 weeks). For all comparisons p ≤ 0.05
was considered statistically significant.
Table I
List of genera of bacteria from the gut analyzed in our study and, their respective controls and primers used to the analysis
Genera Control strain Reference nº Primers (forward and reverse)
Bifidobacterium sp B. longum ATCC 15707 F:5’-CTC CTG GAA ACG GGT GG-3’R:5’-GGT GTT CTT CCC GAT ATC TAC A-3’
Lactobacillus sp L.acidophillus ATCC 4356 F:5’-AGC AGT AGG GAA TCT TCC A-3’R:5’-CAC CGC TAC ACA TGG AG-3’
Bacteroides sp B. fragiles ATCC 43859 F:5’- TAGTTTGTTGGCGGGGTAAC -3’R:5’- GGCTGGTTCAGACTCTCGTC -3’
Clostridium sp C.perfringens ATCC 13124 F:5’-GTG AAA TGC GTA GAG ATT AGG AA-3’R:5’-GAT YYG CGA TTA CTA GYA ACT C-3’
Escherichia coli E. coli ATCC 25922 F:5’ GTT AAT ACC TTT GCT CAT TGA 3’R:5’ ACC AGG GTA TCT AAT CCT GTT 3’
ATCC: American Type Culture Collection.
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RESULTS
Patients
Sixty constipated woman were enrolled (fiber n =
28; placebo n = 32); 2 of them left voluntarily in the
study (both from fiber group) and 12 were excluded
due to loss of follow up (fiber n = 4; placebo n = 8).
Randomization was considered adequate since no dif-
ferences in relation to the means of descriptive charac-
teristics (p ≥ 0.2772, table II) were found between
groups. All enrolled constipated woman were clini-
cally followed and 32 of them submitted to fecal quan-
tification of differential bacteria and short-chain fatty
acids (fiber group n = 14; placebo group n = 18).
Fecal bacteria
By comparing selective bowel bacteria before and
after treatment, the fiber group decreased and placebo
group increased the amounts of total Clostridium sp;
these differences between groups were significant
(table III). We did not find differences in the amounts
of fecal Bifidobacterium, Lactobacillus, Bacteroides,
or Escherichia coli (table IV) between the groups and
studied periods.
SCFA fecal concentration 
The mean of the absolute amount of fecal acetic,
isobutyric, butyric, and valeric acids did not differed
between fiber and placebo groups in any evaluated
period (table IV). Fecal isovaleric acid increased in
placebo group (before versus after treatment), but this
difference was not significant between the treatments
(placebo versus fiber) (table IV). 
Treatment efficacy
There was an increased frequency of weekly bowel
movements and patient satisfaction in both treatment
groups, with no differences between groups (tables V
and VI, respectively).
Discussion
Our trial shows that a fiber mixture of inulin with
agar gum can benefit the treatment of female constipa-
tion by reducing the amount of pathogenic bacteria
Clostridium sp.
Among the 100 bacterial species included in the
Clostridium genera there are several important human
Table II
Descriptive data of patients distributed in fiber and placebo groups
Group Age BW BH BMI SBP DBP HR T(y) (kg) (cm) (kg/m2) (mmHg) (mmHg) (b/min) (Cº)
Fiber 36.1 63.7 160.5 24.75 117.6 79.2 83.1 36.1
Placebo 40.2 66.0 160.6 25.45 117.0 77.4 81.4 36.2
p value 0.2772 0.8995 0.9641 0.8919 0.9429 0.4985 0.3935 0.2902
BW: Body weight; BH: Body height; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; T: Temperature. Student t test.
Table III
Fecal volume of selective bacteria (cells/μl) in constipated women treated with fiber or placebo
Bacteria sp Treatment
Mean ± standard deviation p2 value
BT AT
p1 value (BT; AT)
Bifidobacterium Fiber 6.63 ± 0.97 6.80 ± 1.28 0.405* (0.378; 0.644)Placebo 6.32 ± 0.93 6.67 ± 0.48 0.053*
Lactobacillus Fiber 4.92 ± 1.17 4.88 ± 1.15 0.876* (0.092; 0.285)Placebo 4.24 ± 1.04 4.49 ± 0.88 0.233*
Bacteroides Fiber 10.10 ± 0.45 10.38 ± 0.41 0.158* (0.717; 0.292)Placebo 9.98 ± 1.15 10.20 ± 0.54 0.494*
Clostridium Fiber 5.23 ± 0.67 4.76 ± 0.92 0.046* (0.769; 0.045*)Placebo 5.14 ± 0.92 5.50 ± 0.91 0.047*
Escherichia Fiber 5.70 ± 1.27 5.54 ± 1.46 0.592* (0.531; 0.410)Placebo 5.41 ± 1.29 5.11 ± 1.41 0.183*
p1 = Before treatment (BT) versus after treatment (AT) within groups.
p2 = Fiber versus placebo in both studied periods (BT and AT).
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pathogens, such as C. botulinum, C. difficile, and C.
perfringes. Clostridium difficile is a major etiological
agent of diarrhea and is now recognized as the primary
cause of hospital acquired colitis in patients receiving
antibiotics, chemotherapeutics, or other drugs that alter
normal flora.19 C. perfringens, used as our control bac-
teria, produces different enterotoxins associated with
diseases including food poisoning and necrotic entero-
colitis.20,21 About 5-20% of antibiotic-associated diar-
rhea cases and sporadic non-food borne diarrhea may
be due to Clostridium perfringens type A, mainly in
geriatric patients and those negative for C. difficile22-24.
Therefore, the reduction in Clostridium bacteria with
oral intake of an inulin/PHGG mixture indicates poten-
tial benefits for gut health.
Currently, dietary fibers such as inulin and PHGG
are associated with the promotion of endogenous
microbial population growth, such as Bifidobacteria
and Lactobacilli.2 These bacteria are beneficial for
intestinal health due to a variety of effects, including
inhibition of pathogenic bacterial growth.2 However, we
did not find changes in the amount of Bifidobacteria and
Lactobacilli. Therefore, we suggest that the decrease of
Clostridium bacteria by prebiotics observed by us could
be due to increased levels of other beneficial bacteria,
which we did not evaluate in this study, or by other
mechanisms independent of the changes in beneficial
microbiota.
The fermentation of prebiotics by microorganisms
of the gastrointestinal tract leads to the production of
SCFA. The SCFA produced in the colon, specifically
acetic acid (2C), propionic acid (3C), and butyrate
(4C), are the main source of energy for the enterocyte.
They also stimulate cell proliferation of the epithelium,
increase visceral blood flow, and promote water and
sodium absorption. SCFA have antibacterial properties
that prevent growth of pathogenic bacteria, such as
reduction of luminal pH that stimulates the growth of
Table IV
Fecal SCFA content (area) of constipated women treated with fiber of placebo
SCFA Treatment
Mean ± standard deviation p2 value
BT AT
p1 value (BT; AT)
Acetic Fiber 5.96 ± 0.85 5.86 ± 0.43 0.666* (0.530; 0.860)Placebo 5.81 ± 0.46 5.88 ± 0.41 0.328*
Isobutyric Fiber 4.97 ± 0.42 4.92 ± 0.61 0.581* (0.133; 0.762)Placebo 4.65 ± 0.73 4.81 ± 0.61 0.077*
Butyric Fiber 5.65 ± 0.87 5.42 ± 0.63 0.315* (0.295; 0.999)Placebo 5.35 ± 0.74 5.42 ± 0.65 0.478*
Isovaleric Fiber 5.20 ± 0.59 5.06 ± 0.78 0.131* (0.355; 0.682)Placebo 4.99 ± 0.73 5.14 ± 0.65 0.031*
Valeric Fiber 5.21 ± 0.77 4.95 ± 0.67 0.200* (0.215; 0.912)Placebo 4.90 ± 0.66 4.98 ± 0.5673 0.258*
p1 = Before treatment (BT) versus after treatment (AT) within groups.
p2 = Fiber versus placebo in both studied periods (BT and AT).
Table V
Frequency of bowel movements in women treated with fiber or placebo
Bowel movement (nº) Fiber Placebo
Week 1 Week 2 Week 3 Week 1 Week 2 Week 3
0 0 1 0 0 0 0
1 1 0 0 3 2 1
2 3 3 1 4 3 1
3 5 3 3 7 1 4
4 3 2 3 1 6 1
> 5 10 13 14 9 12 16
Mean ± SD 5.32 ± 4.66 5.82 ± 4.14 5.95 ± 2.50 4.41 ± 3.06 5.17 ± 3.21 6.70 ± 3.83
Fiber versus placebo (p)
Week 1 Week 2 Week 3
+0.90 (3.91) +0.65 (3.68) -0.74 (3.27)
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Lactobacilli and Bifidobacteria and direct suppression
of pathogenic bacteria.13 However, we did not observe
changes in the fecal concentration of SCFA between
the treatments in the present study.
Different factors related to stool collection without
professional supervision could contribute to lack of
observed changes in SCFA. Small stool sample weight
could lead to sampling errors, as the entire bowel does
not containa homogenous distribution of SCFA. Sam-
ples transportation was performed after patients’ calling
to inform us of its collection, and we could not control
the time that samples remained waiting to be adequately
stored. In addition, SCFA are volatile and can be rapidly
lost at physiological pH values, and perhaps our stool
samples should have been stabilized by acidification
prior to freezing.25 On the other hand, it is also possible
that there was an increased production of SCFA that
were consumed by enterocytes and resident bacteria. 
In agreement with our study, previous authors
showed that the ingestion of inulin was able to shorten
the orofecal transit time and improve stool consistency
in subjects suffering from constipation, but did not
change concentrations of the abundant SCFA (acetate,
propionate) and fecal contents of Lactobacillus aci-
dophilus and Bifidobacterium lactis.26 These authors
did not evaluate the stool composition of pathogenic
bacteria.
As long we had controlled the treatment with inulin
and PHGG by using placebo, from our data it is not
possible to infer if the mixture of two fibers can poten-
tiates it individual effect. In a previous study of 188
adult irritable bowel syndrome patients, PHGG was as
effective as a high fiber diet in improving pain and
bowel habits, and was better tolerated by patients.
Another study in childhood constipation found compa-
rable benefits between a fluid fiber mixture and iso-
lated lactulose.7,27
Interestingly, although placebo treatment did not
change the amount of pathogenic bacteria, it improved
bowel movements and patient satisfaction. Maltodex-
trin was chosen as placebo control because it is an eas-
ily absorbed and digested carbohydrate that escapes
bacterial fermentation in the colon and does not inter-
fere in microbial ecology of the gastrointestinal tract,
gut metabolism, and function. Therefore, our data sug-
gest that improvement of bowel movements and
patient satisfaction after treatment with placebo may be
due to the placebo effect. 
The placebo effect has been widely documented by
randomized, placebo-controlled drug studies. The main
theories proposed to explain the placebo effect include
the conditioning theory (placebo effect as a conditioned
response) and the mentalistic theory (patient’s expecta-
tion as the primary cause of the placebo effect).28 Brain
imaging has demonstrated that placebo can mimic the
effect of the active drugs by activating the same brain
areas.29 This is the case for placebo-dopamine in Parkin-
son’s disease and for placebo-analgesics.30,31
Considering that our study included women from a
health care institution with greater awareness of the
potential benefits of using fiber for the treatment of
constipation, it is possible that our participants experi-
enced a placebo effect. Beneficial effects of fiber ver-
sus placebo were found in studies performed in chil-
dren, who are less susceptive to the placebo effect.32,33
In conclusion, a mixture of inulin and PHGG gave
comparable clinical results to placebo in the treatment
of female constipation, but had an additional beneficial
effect on gut microbiota by decreasing the amount of
pathological bacteria of the Clostridium genera.
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